Hadlima (Adalimumab-Bwwd) Patent Expiration, LOE Window & CMS Spending

Hadlima (Adalimumab-Bwwd) by Samsung Bioepis: Biologic BLA (Purple Book Regime), 0 AB generics, $1.4M 2024 CMS Part D & Medicaid spend, and $1,038 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSamsung Bioepis
FDA Application & PathwayB761059 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$295K
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,038 intro WAC)